Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 as first-line monotherapy or combination therapy for KRAS G12D-mutant advanced non-small cell lung cancer
CTR20261083Phase 2Active
- Sponsor
- GenFleet Therapeutics
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GFH375 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by GenFleet Therapeutics. Primary endpoint: Objective response rate. Started May 2026; status: active.
02
Drugs
GFH375
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261083.